日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Understanding nerve-tumor interactions: From basic biology to therapeutic innovation

了解神经肿瘤相互作用:从基础生物学到治疗创新

Sun, Liangzhan; Li, Xia; Wang, Yaxuan; Wang, Jingxuan; Xie, Renrui; Zhang, Ningyi; Zhang, Zemin

ADARp110 promotes hepatocellular carcinoma progression via stabilization of CD24 mRNA

ADARp110通过稳定CD24 mRNA促进肝细胞癌进展

Sun, Liangzhan; Hu, Pengchao; Yang, Hui; Ren, Jun; Hu, Rong; Wu, Shasha; Wang, Yanchen; Du, Yuyang; Zheng, Jingyi; Wang, Fenfen; Gao, Han; Yan, Jingsong; Yuan, Yun-Fei; Guan, Xin-Yuan; Xiao, Jia; Li, Yan

USP39 promotes hepatocellular carcinogenesis through regulating alternative splicing in cooperation with SRSF6/HNRNPC.

USP39 与 SRSF6/HNRNPC 协同作用,通过调节选择性剪接促进肝细胞癌的发生

Zheng Jingyi, Wu Shasha, Tang Mao, Xi Shaoyan, Wang Yanchen, Ren Jun, Luo Hao, Hu Pengchao, Sun Liangzhan, Du Yuyang, Yang Hui, Wang Fenfen, Gao Han, Dai Ziwei, Ou Xijun, Li Yan

UHRF1 inhibition epigenetically reprograms cancer stem cells to suppress the tumorigenic phenotype of hepatocellular carcinoma.

UHRF1 抑制通过表观遗传学手段重编程癌症干细胞,从而抑制肝细胞癌的致瘤表型

Wang Yanchen, Hu Pengchao, Wang Fenfen, Xi Shaoyan, Wu Shasha, Sun Liangzhan, Du Yuyang, Zheng Jingyi, Yang Hui, Tang Mao, Gao Han, Luo Hao, Lv Yue, Yan Jingsong, Ou Xijun, Li Yan

MAEL Augments Cancer Stemness Properties and Resistance to Sorafenib in Hepatocellular Carcinoma through the PTGS2/AKT/STAT3 Axis

MAEL通过PTGS2/AKT/STAT3轴增强肝细胞癌的干细胞特性和对索拉非尼的耐药性

Shi, Chaoran; Kwong, Dora Lai-Wan; Li, Xue; Wang, Xia; Fang, Xiaona; Sun, Liangzhan; Tang, Ying; Guan, Xin-Yuan; Li, Shan-Shan